S100A4 and renal cell carcinoma: However, due to the non-specificity of conventional biomarkers, such as αSMA, FAP, PDGFRα/β, and FSP1 (S100A4) (13), a deficiency of specific biomarkers to distinguish CAFs from other components in the TME presents a challenge to the identification of potential functions and potential as a target for RCC treatment.